Researchers unveiled an enzyme-independent continuous glucose monitoring approach using an acoustically readable microneedle patch (ARMPatch). The device is designed to convert ultrasound interactions at the skin level into glucose-relevant signals without relying on enzymatic chemistry that can degrade over time. If validated in further human studies, the platform could lower barriers for CGM deployment by improving stability and potentially simplifying sensor manufacturing and calibration. The approach sits at the intersection of materials science, biomedical engineering, and wearable sensing. The development adds to competitive pressure in diabetes monitoring as device makers and biotech partnerships race toward more durable, accurate, and scalable CGM form factors.